InFocus

InFocus Therapeutics is a next-generation biotechnology company specializing in the discovery and development of RNA-targeted small molecule therapeutics. Founded in 2023 and headquartered in Cambridge, Massachusetts, the company utilizes a proprietary AI-driven generative chemistry platform to identify compounds that modulate RNA-based biological processes, such as splicing and gene expression. Their pipeline primarily targets high-impact conditions in oncology and neuromuscular diseases, including spinal muscular atrophy (SMA) and neurodegenerative disorders. By combining computational modeling with structure-guided chemistry, InFocus aims to address "undruggable" targets that traditional protein-focused approaches cannot reach. The company maintains a global presence with operations in the United States, France, and Taiwan.